Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: A<i> Post</i><i> Hoc</i> Analysis From the HOST-EXAM Extended Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Keehwan | - |
dc.contributor.author | Kang, Jeehoon | - |
dc.contributor.author | Park, Kyung Woo | - |
dc.contributor.author | Park, Tae -Ho | - |
dc.contributor.author | Kim, Bum Soo | - |
dc.contributor.author | Lim, Sang Wook | - |
dc.contributor.author | Cho, Yoon Haeng | - |
dc.contributor.author | Jeon, Dong Woon | - |
dc.contributor.author | Kim, Sang-Hyun | - |
dc.contributor.author | Yang, Han-Mo | - |
dc.contributor.author | Kang, Hyun-Jae | - |
dc.contributor.author | Han, Jung-Kyu | - |
dc.contributor.author | Shin, Eun-Seok | - |
dc.contributor.author | Koo, Bon -Kwon | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2024-06-11T07:32:30Z | - |
dc.date.available | 2024-06-11T07:32:30Z | - |
dc.date.issued | 2024-01 | - |
dc.identifier.issn | 0828-282X | - |
dc.identifier.issn | 1916-7075 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/26054 | - |
dc.description.abstract | Backgrounds: The HOST-EXAM Extended study reported the benefit of clopidogrel monotherapy over aspirin monotherapy in secondary prevention after percutaneous coronary intervention (PCI). This age-specific subgroup analysis of the study aimed to assess the impact of age on antiplatelet monotherapy after PCI. Methods: We analysed data from the per-protocol population (4717 patients) with a median follow-up of 5.8 years. The old age group comprised 2033 patients (43.1%), defined as those 65 years of age or older. The primary end point was the composite of all-cause death, nonfatal myocardial infarction, stroke, readmission due to acute coronary syndrome (ACS), and Bleeding Academic Research Consortium (BARC) bleeding type 3 or greater. The secondary end points were thrombotic composite outcomes and any bleeding. Results: Age correlated with an elevated risk of adverse events, particularly from age 65. Clopidogrel monotherapy was associated with a reduction of the primary end point in both the old age group (19.4% vs 23.1%, hazard ratio [HR] 0.802, 95% confidence interval [CI] 0.664-0.968; P = 0.022) and the young age group (7.8% vs 11.7%, HR 0.646, 95% CI 0.506-0.825; P < 0.001), without significant interaction (interaction P = 0.167). These findings were consistent for the secondary composite thrombotic end point and any bleeding events (interaction P value of secondary thrombotic end point: 0.786; interaction P value of any bleeding end point: 0.565). Consistent results were observed in analyses with a 75-year age cutoff and in subgroup analyses by 10-year age intervals. Conclusions: In patients requiring antiplatelet monotherapy after PCI, occurrence of both ischemic and bleeding events dramatically increased from age 65. The beneficial impact of clopidogrel over aspirin monotherapy was consistent regardless of age. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Impact of Age on Antiplatelet Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: A<i> Post</i><i> Hoc</i> Analysis From the HOST-EXAM Extended Study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.cjca.2023.09.021 | - |
dc.identifier.scopusid | 2-s2.0-85179609918 | - |
dc.identifier.wosid | 001166736800001 | - |
dc.identifier.bibliographicCitation | CANADIAN JOURNAL OF CARDIOLOGY, v.40, no.1, pp 43 - 52 | - |
dc.citation.title | CANADIAN JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 40 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 43 | - |
dc.citation.endPage | 52 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | SECONDARY PREVENTION | - |
dc.subject.keywordPlus | ASPIRIN MONOTHERAPY | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CLOPIDOGREL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PRASUGREL | - |
dc.subject.keywordPlus | DISEASE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.